Monoclonal gammopathies (MG) comprise a spectrum of disorders, from the pre-malignant Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM), which is associated with significant morbidity and mortality.1 A hallmark of MG is the production of a monoclonal protein (M-protein) (except in cases of non-secretory MM).2 Some synonyms include ‘paraprotein’, ‘M-component’, and ‘monoclonal immunoglobulin’. The gene discussed is MYOM2; the disease is Miyoshi myopathy.